Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cerasus humilis polyphenol refers to the mixture of polyphenolic compounds naturally present in the fruit of *Cerasus humilis* (Chinese dwarf cherry or Prunus humilis), a wild fruit tree endemic to China. These polyphenols, principally procyanidin B2, cyanidin-3-glucoside, pelargonidin-3-glucoside, various anthocyanins, flavonoids, and cinnamoylquinic acids, are recognized for their substantial antioxidant, anti-inflammatory, and anti-obesity activities. Mechanistically, cerasus humilis polyphenol reduces adipocyte differentiation by downregulating transcription factors such as PPARγ and C/EBPα, modulates lipid and glucose metabolism, decreases inflammatory mediators (e.g., TNF-α, IL-6, MCP1), improves oxidative stress parameters, and enhances Sirt1 expression. It has shown potential benefit in preclinical animal models to mitigate obesity, dyslipidemia, and oxidative stress, with additional evidence for immune modulation and potential applications in functional foods or dietary supplements[1][3][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cerasus humilis polyphenol.